|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serotonin 5-HT2C receptor is a G-protein coupled excitatory receptor that regulates several biochemical pathways and has been implicated in obesity, mental state, sleep cycles, autism, neuropsychiatric disorders and neurodegenerative diseases.
|
30862860 |
2019 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Since 5-HT2CR is a class A G protein-coupled receptor (GPCR), drug discovery efforts have traditionally pursued the activation of the receptor through synthetic ligands with agonists proposed for the treatment of obesity, substance use disorders and impulse control disorders while antagonists may add value for the treatment of anxiety, depression and schizophrenia.
|
31288724 |
2019 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Since 5-HT2CR is a class A G protein-coupled receptor (GPCR), drug discovery efforts have traditionally pursued the activation of the receptor through synthetic ligands with agonists proposed for the treatment of obesity, substance use disorders and impulse control disorders while antagonists may add value for the treatment of anxiety, depression and schizophrenia.
|
31288724 |
2019 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To explore further, the present study aimed to assess the influence of DRD2 -141 C Ins/Del, Taq1A and HTR2A -1438 G/A, 102T/C and HTR2C -759 C/T genetic polymorphisms in response to risperidone in patients with schizophrenia.
|
30332506 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
The serotonin receptor 2C (5HT2C) is an important drug target to treat obesity and depression.
|
29969651 |
2018 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The serotonin receptor 2C (5HT2C) is an important drug target to treat obesity and depression.
|
29969651 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, POLR1B, POLE3, POLD3, and HTR2C might play important roles in obese PCOS via involvement of pyrimidine metabolism and calcium signaling pathway.
|
29601948 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The serotonin receptor 2C (5HT2C) is an important drug target to treat obesity and depression.
|
29969651 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The serotonin (5-HT) 5-HT2A receptor (5-HT2AR) and 5-HT2C receptor (5-HT2CR) in the central nervous system are implicated in a range of normal behaviors (e.g., appetite, sleep) and physiological functions (e.g., endocrine secretion) while dysfunctional 5-HT2AR and/or 5-HT2CR are implicated in neuropsychiatric disorders (e.g., addiction, obesity, schizophrenia).
|
30157263 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Medications targeting 5-hydroxytryptamine (5-HT; serotonin) 2C receptors (htr2c; 5-HT<sub>2C</sub>R) improve obesity.
|
30146485 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The serotonin (5-HT) 5-HT2A receptor (5-HT2AR) and 5-HT2C receptor (5-HT2CR) in the central nervous system are implicated in a range of normal behaviors (e.g., appetite, sleep) and physiological functions (e.g., endocrine secretion) while dysfunctional 5-HT2AR and/or 5-HT2CR are implicated in neuropsychiatric disorders (e.g., addiction, obesity, schizophrenia).
|
30157263 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Agomelatine (AGO), an agonist at melatonergic MT1/MT2 receptors and antagonist at 5-HT2C receptors, increases dopamine and norepinephrine in the prefrontal cortex and may therefore have the potential of improving neurocognition in patients with schizophrenia.
|
29912792 |
2018 |
|
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, HTR2C genetic variants may be involved in the susceptibility to MS in patients treated with atypical antipsychotics.
|
29441581 |
2018 |
|
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An association has been found between the C allele of the rs1414334 polymorphism in the HTR2C gene and the metabolic syndrome in psychiatric patients.
|
28492956 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
It examines the growing evidence that altered levels of these SNORDs and/or their host-gene transcripts may be a primary cause of Prader-Willi syndrome (PWS; a rare disorder characterized by overeating and obesity) as well as abnormalities in signaling through the 5-HT2C serotonin receptor.
|
28296064 |
2017 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
-759C>T Polymorphism of the HTR2C Gene is Associated with Second Generation Antipsychotic-Induced Weight Gain in Female Patients with Schizophrenia.
|
27414739 |
2017 |
|
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found associations with outcomes such as increases in BMI and metabolic syndrome for variants in genes such as LEP and HTR2C.
|
28879574 |
2017 |
|
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study confirms a high prevalence of metabolic side effects with clozapine and suggests higher clozapine level and pharmacogenetic markers in CYP2C19, LEP, LEPR, and HTR2C receptors as important predictors of BMI and metabolic syndrome.
|
27681143 |
2017 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
The development of drugs that specifically target 5-HT2C receptors will allow for better understanding of their involvement in the pathophysiology of psychiatric disorders including schizophrenia, anxiety, and depression.
|
26739950 |
2016 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The development of drugs that specifically target 5-HT2C receptors will allow for better understanding of their involvement in the pathophysiology of psychiatric disorders including schizophrenia, anxiety, and depression.
|
26739950 |
2016 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We aim to investigate whether the -759C÷T polymorphism in 5-HTR2C gene was associated with weight change and hyperinsulinemia in Romanian pediatric patients with schizophrenia and bipolar disorders.
|
28174802 |
2016 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The development of drugs that specifically target 5-HT2C receptors will allow for better understanding of their involvement in the pathophysiology of psychiatric disorders including schizophrenia, anxiety, and depression.
|
26739950 |
2016 |
|
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Several genes showed strong evidence for an association with MetS in patients with schizophrenia, including the fat mass and obesity associated gene (FTO), leptin and leptin receptor genes (LEP, LEPR), methylenetetrahydrofolate reductase (MTHFR) gene and the serotonin receptor 2C gene (HTR2C).
|
26621002 |
2016 |
|
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A pharmacogenomic analysis revealed the presence of the 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled (HTR2C) -759C genotype which is related to increased risk for metabolic syndrome.
|
26359410 |
2016 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results of the present study do not support a major role of SNPs LEP rs7799039, ADIPOQ rs1501299 and HTR2C rs1414334 in the regulation of weight gain or association of serum levels of leptin and adiponectin and corresponding studied SNPs in patients with schizophrenia on clozapine treatment.
|
25284335 |
2015 |